drugset / Trial / NCT00250705
Trial of Aripiprazole in the Treatment of CD in Adolescents
NaSingle-groupOpen-labelTreatment
Summary
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder. The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). For the first two weeks of the study, the dose will be flexible based on response and tolerance and thereafter will remain fixed.
Timeline
- Start
- 2004-11-17
- Primary completion
- 2009-03-23
- Completion
- 2009-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 1 mg | — |
| Subject | Aripiprazole | Other / unclassified | 2 mg | — |
| Subject | Aripiprazole | Other / unclassified | 5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 10 mg | — |
| Subject | Aripiprazole | Other / unclassified | 20 mg | — |